ADLARITY Drug Patent Profile
✉ Email this page to a colleague
When do Adlarity patents expire, and what generic alternatives are available?
Adlarity is a drug marketed by Corium and is included in one NDA. There are nine patents protecting this drug.
This drug has eighty-nine patent family members in eleven countries.
The generic ingredient in ADLARITY is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adlarity
A generic version of ADLARITY was approved as donepezil hydrochloride by ACI on May 31st, 2011.
Summary for ADLARITY
International Patents: | 89 |
US Patents: | 9 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 160 |
Patent Applications: | 4,015 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ADLARITY |
What excipients (inactive ingredients) are in ADLARITY? | ADLARITY excipients list |
DailyMed Link: | ADLARITY at DailyMed |
Pharmacology for ADLARITY
Drug Class | Cholinesterase Inhibitor |
Mechanism of Action | Cholinesterase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ADLARITY
US Patents and Regulatory Information for ADLARITY
ADLARITY is protected by nine US patents and one FDA Regulatory Exclusivity.
Patents protecting ADLARITY
Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Donepezil transdermal delivery system
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Donepezil transdermal delivery system
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Systems and methods for long term transdermal administration
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Systems comprising a composite backing and methods for long term transdermal administration
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Methods for treating alzheimer's disease with donepezil transdermal system
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
Donepezil transdermal delivery system
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting ADLARITY
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-001 | Mar 11, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-001 | Mar 11, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-001 | Mar 11, 2022 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Corium | ADLARITY | donepezil hydrochloride | SYSTEM;TRANSDERMAL | 212304-002 | Mar 11, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ADLARITY
See the table below for patents covering ADLARITY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2017302307 | Sodium bicarbonate in situ conversion driven transdermal delivery of amine drug | ⤷ Try a Trial |
Japan | 2019523268 | 塩薬物のin situでの塩から中性の薬物変換による、低溶解度または不安定非イオン化中性薬物の経皮配合物および送達方法 | ⤷ Try a Trial |
Japan | 7153010 | ⤷ Try a Trial | |
Japan | 2019525932 | 炭酸水素ナトリウムのin situ変換で促進されたアミン薬物の経皮送達 | ⤷ Try a Trial |
Canada | 3032044 | SYSTEME D'ADMINISTRATION TRANSDERMIQUE DE DONEPEZIL (DONEPEZIL TRANSDERMAL DELIVERY SYSTEM) | ⤷ Try a Trial |
South Korea | 20190035801 | 아민 약물의 나트륨 바이카보네이트 제자리 전환 구동된 경피성 전달 | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ADLARITY
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0296560 | 2/1998 | Austria | ⤷ Try a Trial | PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214 |
0296560 | SPC/GB97/023 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |